Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS
BackgroundCompared with platinum-based chemotherapy, the combination of enfortumab vedotin and pembrolizumab (EV + Pembro) achieves higher durable response rates and improves survival outcomes in patients with locally advanced or metastatic urothelial …